Epigenome

Overview

The epigenome encompasses all heritable and dynamic chemical modifications to DNA and its packaging proteins (histones) that influence how genes are read — without changing the DNA sequence itself. While the genome is largely fixed, the epigenome is a responsive layer that records developmental history, environmental experience, and cellular identity.

Epigenetic regulation is central to cell differentiation, homeostasis, memory, aging, and disease. It also provides a substrate through which peptide signaling — sometimes acutely, sometimes over months — leaves lasting marks on cellular behavior.

Detailed Explanation

DNA methylation

The addition of a methyl group to the 5-position of cytosine (5-methylcytosine, 5mC), typically at CpG dinucleotides. Dense methylation of promoter regions usually silences genes; methylation within gene bodies correlates with active transcription. The enzymes responsible are DNMT1, DNMT3A, and DNMT3B; demethylation proceeds via TET enzymes and the base excision repair pathway.

Histone modifications

Histones H2A, H2B, H3, and H4 carry dozens of post-translational modifications on their flexible N-terminal tails: acetylation, methylation, phosphorylation, ubiquitylation, SUMOylation, and more. Specific marks correlate with functional states:

• H3K4me3 — active promoters
• H3K27me3 — facultative heterochromatin (Polycomb-repressed)
• H3K9me3 — constitutive heterochromatin
• H3K27ac — active enhancers
• H3K36me3 — active gene bodies

The "histone code" is read by chromatin-binding proteins (BRDs, chromodomains, PHD fingers) that recruit chromatin remodelers and transcription factors.

Chromatin remodeling

ATP-dependent complexes (SWI/SNF, ISWI, CHD, INO80) reposition or evict nucleosomes to expose or hide regulatory sequences.

Non-coding RNAs

Long non-coding RNAs (Xist, HOTAIR) and small RNAs (miRNAs, piRNAs) contribute to epigenetic silencing by guiding modifier complexes to target loci.

Epigenetic Writers, Readers, Erasers

• Writers — deposit marks (DNMTs, HATs, KMTs)
• Readers — recognize marks (bromodomains, chromodomains, MBDs)
• Erasers — remove marks (TETs, HDACs, KDMs)

Many readers and writers are drug targets. HDAC inhibitors (vorinostat, romidepsin) and EZH2 inhibitors (tazemetostat) are approved oncology therapies.

Epigenome and Environment

The epigenome responds to:

• Diet — methyl donors (folate, B12, choline) shape methylation
• Stress — hormones alter histone acetylation at stress-responsive genes
• Exercise — modifies methylation at metabolic gene promoters
• Microbiome — microbial metabolites (butyrate, propionate) directly inhibit HDACs
• Toxins — arsenic, tobacco smoke leave epigenetic signatures

Relevance to Peptide Therapeutics

Peptide signals can propagate into the epigenome through several routes:

• Signaling to chromatin-modifying enzymes — kinase cascades phosphorylate HATs and HDACs, changing their activity
• Transcription factor recruitment of cofactors — many transcription factors bring p300/CBP (histone acetyltransferases) or HDACs to their target loci
• Metabolic remodeling — peptides that shift metabolism change levels of SAM, acetyl-CoA, α-ketoglutarate, NAD+ — all substrates or regulators of epigenetic enzymes
• Cellular identity changes — stem cell peptides and growth factors drive differentiation programs that reshape chromatin state
• Tachyphylaxis and adaptation — sustained agonist exposure can induce stable epigenetic changes that outlast the drug

Clinical and Research Implications

• Cancer — aberrant methylation, histone mutations, and chromatin remodeler mutations drive many tumors.
• Neurodegeneration and psychiatric disease — epigenetic dysregulation of synaptic and stress-response genes is well documented.
• Aging — "epigenetic clocks" based on methylation patterns predict biological age.
• Fetal programming — maternal nutrition and stress leave epigenetic marks that influence offspring physiology.

Summary

The epigenome integrates genetic information with cellular and environmental context. It is the mechanistic bridge between short-term peptide signaling and the long-term, sometimes heritable, changes that define health and disease.